ClinicalTrials.gg
RecruitingNCT07447791WISDOM UKUpdated Mar 5, 2026

WISDOM UK: Low Dose-intensity Versus Standard Dose-intensity CRRT in Critically Ill Patients

An interventional study of low intensity of CRRT and usual intensity of CRRT in Acute Kidney Injury (Nontraumatic) and Dialysis; Complications, sponsored by Guy's and St Thomas' NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Guy's and St Thomas' NHS Foundation Trust · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Feb 2025, registered Feb 2026).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Acute Kidney Injury by Guy's and St Thomas' NHS Foundation Trust — 3 open to participants now, 5 under way, none of them phase 3. Acute Kidney Injury · Guy's and St Thomas' NHS Foundation Trust.

Started
2025
the only one that year
No phase
3 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Acute Kidney Injury by Guy's and St Thomas' NHS Foundation Trust, this one is the only one that started in 2025, is one of 3 with no phase, and was the 12th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

3 of the 12 studies in Acute Kidney Injury by Guy's and St Thomas' NHS Foundation Trust are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Acute Kidney Injury by Guy's and St Thomas' NHS Foundation Trust, or all of them as a file.
02

Study summary

Acute kidney injury is a potentially life threatening condition which affects 1 in 2 patients in the Intensive Care Unit (ICU). Patients often need dialysis treatment, also called renal replacement therapy. Renal replacement therapy is a treatment that removes toxins and excess fluid from the blood stream. It consists of having a small plastic catheter in a vein in the neck or in the groin through which blood flows through a dialysis machine and is cleansed and excess water is removed. The cleansed blood is then returned to the patient via the same catheter.

One of the major areas of uncertainty for doctors in the ICU is "What is the right intensity of renal replacement therapy for patients with acute kidney injury?" A higher intensity indeed removes more toxins but also removes other substances in the blood, including vitamins, nutrients and important medications. The current usual dose is around 25 ml/kg/hr but clinical practice in the UK is very variable and some patients routinely receive higher doses and some get lower doses. Data from large databases worldwide have suggested that a lower dose is safe and effective and may potentially allow the kidneys to recover faster but confirmation is lacking.

In this study, the investigators investigate whether renal replacement therapy at a lower intensity is as effective and safe as currently used doses. Participants will be randomised to receiving renal replacement therapy at usual or lower intensity. There will be no change to any other aspects of treatment.

The results will inform the investigators whether the study protocol is feasible and how best to design a future larger research study.

Read the detailed description

Acute kidney injury is a potentially life threatening condition which affects 1 in 2 patients in the Intensive Care Unit (ICU). Patients often need dialysis treatment, also called renal replacement therapy. Renal replacement therapy is a treatment that removes toxins and excess fluid from the blood stream. It consists of having a small plastic catheter in a vein in the neck or in the groin through which blood flows through a dialysis machine and is cleansed and excess water is removed. The cleansed blood is then returned to the patient via the same catheter.

One of the major areas of uncertainty for doctors in the ICU is "What is the right intensity of renal replacement therapy for patients with acute kidney injury?" A higher intensity indeed removes more toxins but also removes other substances in the blood, including vitamins, nutrients and important medications. The current usual dose is around 25 ml/kg/hr but clinical practice in the UK is very variable and some patients routinely receive higher doses and some get lower doses. Data from large databases worldwide have suggested that a lower dose is safe and effective and may potentially allow the kidneys to recover faster but confirmation is lacking.

In this study, the investigators investigate whether renal replacement therapy at a lower intensity is as effective and safe as currently used doses. Participants will be randomised to receiving renal replacement therapy at usual or lower intensity. There will be no change to any other aspects of treatment.

The investigators aim to recruit 20 patients in the UK. Fully anonymised results will be shared with researchers in Canada who are conducting the same study.

03

Conditions studied

  • Acute Kidney Injury (Nontraumatic)
  • Dialysis; Complications

Browse trials for

Keywords

  • renal replacement therapy
  • dose
  • acute kidney injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥ 18 years
  • patient weight ≥ 55 kg
  • plan to start CRRT or within 24 hours of having started CRRT for AKI
  • expected to survive and receive CRRT for a duration of ≥ 48 hours

Exclusion criteria

Exclusion Criteria:

  • indication for sustained higher dose-intensity CRRT
  • end-stage kidney disease receiving maintenance dialysis
  • previous receipt of RRT for AKI during the current hospitalization
  • inability to comply with the requirements of the study protocol
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Low dose RRT

    dose of CRRT 10-15ml/kg/hr

    Procedure: low intensity of CRRT

  • Active comparator
    standard dose RRT

    usual intensity CRRT at dose determined by clinical team

    Procedure: usual intensity of CRRT

Interventions

  • Procedurelow intensity of CRRT

    usual intensity CRRT

  • Procedureusual intensity of CRRT

    usual intensity

06

What researchers measure

Primary outcomes

  1. total delivered effluent rate

    difference in the total delivered effluent rate per patient

    Time frame: 7 days

Secondary outcomes

  1. Feasibility endpoints

    number of enrolled patients

    Time frame: 12 months

Other outcomes

  1. adverse events

    number of trial related adverse events per patient

    Time frame: 14 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jan 2027, 23 months after the start.

Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 23 months is below that.

Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 3, 2026
StartActual
Feb 15, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Mar 30, 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07447791
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Feb 15, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

Marlies Ostermann, PhD
Contact
m.ostermann@nhs.net
+442071883036
Gillian Radcliffe
Contact
gill.radcliffe@nhs.net
00442071883036
Gillian Radcliffe
study chair · Guy's & St. Thomas Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion